Selecta Biosciences (SELB) Tops Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq falls as Alphabet set for record loss amid AI spending woes
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
- Moderna stock rises on latest cancer vaccine data publication
Selecta Biosciences Reports First Quarter 2020 Financial Results
May 7, 2020 7:30 AM EDT- Topline data announcement from the ongoing head-to-head COMPARE trial of SEL-212 remains on schedule for Q3 2020 -
- Phase 3 clinical program of SEL-212 to commence in 2H 2020 -
- Ongoing COVID-19 pandemic has not materially impacted COMPARE trial progress; continual ongoing assessment and coordination with CRO and clinical sites taking place -
- Gene therapy program in collaboration with AskBio remains on track to enter the clinic by Q4 2020 -
- Company to host conference call today... More



